{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-26-000006","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2026-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.022024+00:00","generated_at":"2026-05-16T03:28:22.567696+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neurocrine reports Q4 2025 revenue $805.5M, EPS $1.48 GAAP; guides INGREZZA 2026 sales $2.7-2.8B","bullets":["Q4 total net product sales $798.3M (+29% YoY); full year $2.83B (+22% YoY).","INGREZZA Q4 sales $657.5M (+7% YoY); full year $2.51B (+9% YoY); 2026 guidance $2.7-2.8B.","CRENESSITY Q4 sales $135.3M (vs $1.7M YoY); full year $301.2M; 2,048 new patient start forms in FY.","GAAP diluted EPS Q4 $1.48 (vs $1.00); full year $4.67 (vs $3.29). Non-GAAP EPS Q4 $1.88 (vs $1.69).","Cash & marketable securities $2.54B at Dec 31, 2025; R&D and SG&A guidance provided for 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-26-000006","json":"https://secwatch.observer/filing/0000914475-26-000006.json","markdown":"https://secwatch.observer/filing/0000914475-26-000006.md","text":"https://secwatch.observer/filing/0000914475-26-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447526000006/0000914475-26-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447526000006/nbix-20260211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:28:22.567696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}